Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 40kWORD 20k
29 March 2019
Question for written answer E-001550-19
to the Commission
Rule 130
María Teresa Giménez Barbat (ALDE)

 Subject:  Use of genome editing technologies in healthcare
 Answer in writing 

As evidenced by the recent debate in Parliament on 12 February 2019, there is a growing interest in and awareness of genome editing technologies. Technologies such as CRISPR‐Cas9 could have the potential to significantly improve healthcare, by providing treatments for previously untreatable patients.

Last year, Commissioner Moedas, conscious of both the bigger picture of genome editing — including possible therapeutic applications — and specific aspects of concern, asked the European Group on Ethics in Science and New Technologies to put together an opinion on genome editing.

Does the Commission support treatments that might involve genome editing?

What action is the Commission taking to support the development of and access to advanced therapy medicinal products (ATMPs), especially genome editing technologies, for patients in the EU?

Would the Commission consider carrying out a Special Eurobarometer public opinion survey on ATMPs, especially genome editing technologies, as a follow-up to the survey ‘Biotechnology and Genetic Engineering: what Europeans think about it in 1993’?

Last updated: 9 April 2019Legal notice - Privacy policy